Antifungal agents, WO2009025733.
BACKGROUND
The incidence and prevalence of serious mycoses continues to be a public health problem. These infections are an important cause of morbidity and mortality, especially in immunocompromised patients. The present patent deals with isolation and characterization of a 'pure' mixture of two novel isoxazolidinone-containing natural products from two new fungal strains. They have the partial structure of secalonic acid and show very good antifungal activity in mammals and plants and also synergism with other active ingredients.


OBJECTIVE
To analyze the activity of the isoxazolidinone-containing compounds in the present patent.


METHODS
To review the discovery and development of antifungal compounds in general and secalonic acid related compounds in particular.


CONCLUSIONS
The research of Parish and collaborators at Merck and Co. has isolated novel antifungal compounds with a new mode of action. These molecules may be considered potential antifungal leads for further clinical study.
Sudhir
Pore Vandana
PV
National Chemical Laboratory, Division of Organic Chemistry, Dr Homi Bhabha Road, Pashan, Pune 411 008, India. vs.pore@ncl.res.in
Ranjan
Deshpande Sunita
DS
Ganpat
Aher Nilkanth
AN
D000818:Animals; D000935:Antifungal Agents / Q000737:chemistry / Q000494:pharmacology*; D001688:Biological Products / Q000494:pharmacology; D015195:Drug Design; D004357:Drug Synergism; D006801:Humans; D016867:Immunocompromised Host; D007555:Isoxazoles / Q000737:chemistry / Q000494:pharmacology*; D009181:Mycoses / Q000188:drug therapy* / Q000401:mortality / Q000503:physiopathology; D010330:Patents as Topic; D010935:Plant Diseases / Q000382:microbiology / Q000628:therapy; D044004:Xanthones / Q000737:chemistry
D000935:Antifungal Agents; D001688:Biological Products; D007555:Isoxazoles; D044004:Xanthones; C009218:secalonic acid